CJC-1295 (no DAC), Ipamorelin, and GHRP-2 is a research peptide blend formulated to investigate synergistic mechanisms of growth hormone release through dual receptor activation. CJC-1295 (Mod GRF 1–29) binds to GHRH receptors, stimulating cAMP/PKA signaling in pituitary somatotrophs, while Ipamorelin and GHRP-2 act as ghrelin receptor (GHS-R1a) agonists engaging Gq/11-mediated calcium mobilization. This combination is used in endocrine research examining GH pulsatility, peptide receptor synergy, and hypothalamic–pituitary signaling modulation.
CJC-1295 (no DAC), Ipamorelin, GHRP-2 (Blend)
$85.00
Disclaimer
This product is furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.




Reviews
There are no reviews yet.